Why the study?
Acute type A aortic dissection is a heterogeneous systemic inflammatory response syndrome, and whether distinct inflammatory subphenotypes exist and respond differently to pharmacotherapies was unknown.
Does ulinastatin treatment interact with inflammatory subphenotypes to improve outcomes in patients with acute type A aortic dissection?
Does ulinastatin treatment interact with inflammatory subphenotypes to improve outcomes in patients with acute type A aortic dissection?
Identification of distinct inflammatory subphenotypes in acute type A aortic dissection correlates with operative mortality and may help predict differential responses to anti-inflammatory therapies like ulinastatin.
Answers are grounded in this paper and cite their sources.
Identifies inflammatory subphenotypes in ATAAD; leaves open whether phenotype-guided therapy improves outcomes.
Background: Acute type A aortic dissection (ATAAD) is a heterogeneous systemic inflammatory response syndrome. Identification of distinct inflammatory phenotypes may allow more precise therapy and improved care. We aim to investigate whether distinct inflammatory subphenotypes exist in ATAAD patients and respond differently to pharmacotherapies. Methods: Retrospective analysis of data sets was conducted from the Additive Anti-inflammatory Actions for Aortopathy & Arteriopathy (5A) III study. Inflammatory subphenotypes were derived among 2008 ATAAD patients who received surgical repair at 11 Chinese hospitals (2016– 2020) using latent class analysis applied to 14 laboratory signatures within 6 hours of hospital admission. Outcomes included operative mortality (Society of Thoracic Surgeons definition), derived subphenotype frequency, and the potential consequences of phenotype frequency distributions on the treatment effects. Results: The median (interquartile range) age of patients was 54 (45– 62) years, and 1423 (70.9%) were male. A two-class (two subphenotype) model was an improvement over a one-class model ( P <· 001), with 1451 (72.3%) patients in the hypoinflammatory subphenotype group and 557 (27.7%) in the hyperinflammatory subphenotype group. Patients with the hyperinflammatory subphenotype had higher operative mortality (71 [12.7%] vs 127 [8.8%]; P =0· 007) than did those with the hypoinflammatory subphenotype. Furthermore, the interaction between ulinastatin treatment and subphenotype is not significant for operative mortality ( P =0.15) but for ventilator time ( P =0· 04). Conclusion: Two subphenotypes of ATAAD were identified in the 5A cohort that correlated with clinical outcomes, with significant interaction effect between anti-inflammatory treatment and subphenotypes for ventilator time, suggesting these phenotypes may help in understanding heterogeneity of treatment effects. Trial Registration: Clinical Trials. Gov: number NCT04918108.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: